Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications

Table 8 Boceprevir

Ref.	n	Design	Treatment	Population	Outcome
Kwo et al[77]	520	Two part randomized clinical trial	Boceprevir	chronic HCV genotype 1 - treatment naïve	Boceprevir has the potential to double the SVR rate compared with standard treatment alone. Insomnia was the only psychiatric illness documented
Bacon et al[75]	403	Placebo controlled, randomized clinical trial	PEGIFN-α-2b/RBV boceprevir, PEGIFN-α-2b/RBV	Retreatment of patients with chronic HCV genotype 1 infection	Boceprevir resulted in significantly higher rates of SVR. Significant onset of depression was not indicated
Poordad et al[76]	1097	Double blind, placebo controlled randomized clinical trial	Boceprevir PEGIFN-α-2b/RBV	Chronic HCV genotype 1 - treatment naïve	Boceprevir significantly increased the rates of SVR. Insomnia was the only psychiatric condition identified as an adverse event

PEGIFN: Pegylated interferon (peginterferon); RBV: Ribavirin; HCV: Hepatitis C virus; SVR: Sustained virologic response.